Palliative sedation for status epilepticus in a patient with progressive multifocal leukoencephalopathy
| Autor: | Alexandre Dubra, Ferdinando Cancelli, Gilbert Zulian |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Drug
Adult Male medicine.drug_class Sedation media_common.quotation_subject Midazolam Status epilepticus Status Epilepticus Refractory medicine Humans Hypnotics and Sedatives Pharmacology (medical) media_common Benzodiazepine business.industry Progressive multifocal leukoencephalopathy Palliative Care Leukoencephalopathy Progressive Multifocal medicine.disease Anesthesiology and Pain Medicine Sedative Anesthesia medicine.symptom business medicine.drug |
| Zdroj: | Journal of painpalliative care pharmacotherapy. 28(4) |
| ISSN: | 1536-0539 |
| Popis: | Palliative sedation is defined as the use of sedative drugs in order to reduce the patient's consciousness in case of refractory symptoms. The most used drug is midazolam, a benzodiazepine with a short half-life administered either intravenously or subcutaneously. We discuss on a clinical case requiring an exceptionally high dosage of midazolam—up to 160 mg iv daily—to achieve palliative sedation. The patient was an HIV positive 29-year-old male who was suffering from progressive multifocal leukoencephalopathy complicated by a refractory status epilepticus and who was suspected of previous benzodiazepines and opioid abuse. In such situations of a suffering brain doses of midazolam to achieve symptom control may be much higher than expected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|